ABSTRACT
OBJECTIVE To evaluate the efficacy and safety of Chinese medicine (Q-14) plus standard care compared with standard care alone in adult with coronavirus disease 2019 (COVID-19).
Study DESIGN Single-center, open label, randomised controlled trial.
SETTING Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.
PARTICIPANTS 204 patients with laboratory confirmed COVID-19 were randomised in to treatment group and control group, which was 102 patients each group.
INTERVENTIONS In treatment group, Q-14 was administrated at 10g (granules), twice daily for 14 days and plus standard care. In control group, patients were given standard care alone for 14 days.
MAIN OUTCOME MEASURE The primary outcome was conversion time of SARS-CoV-2 viral assay. Adverse events were analyzed in the safety population.
RESULTS Among 204 patients, 195 were analyzed according to the intention to treat principle. There were 149 patients (71 vs. 78 in treatment group and control group respectively) turning to negative via SARS-CoV-2 viral assay. No statistically significance showed in conversion time between treatment group and control group (FAS: Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 67.92 vs. 81.44; P=0.051.). Time to recovery of fever was shorter in treatment group as compared in control group. The disappearance rate of symptom in cough, fatigue, chest discomfort was significantly higher in treatment group. In chest computed tomography (Chest CT) examinations, overall evaluation of chest CT examination after treatment compared with baseline showed more patients improved in treatment group .There were no significant differences in the other outcomes.
CONCLUSION Administration of Q-14 on standard care for COVID-19 was useful for improvement of symptoms (such as fever, cough, fatigue and chest discomfort), while did not result in a significantly higher probability of negative conversion of SARS-CoV-2 viral assay. No serious adverse events were reported.
TRIAL REGISTRATION ChiCTR2000030288
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2000030288
Funding Statement
The study was funded by National Key Research and Development Plan for the Emergency Management of Novel Coronavirus Pneumonia (No. 2020YFC0841500)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol had been approved by the Ethics Review Committee of China Academy of Chinese Medical Sciences.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Research data was recorded using Medroad Cloud Electronic Data Capture System (Jiangsu Famous Medicine Science and Technology Ltd.) http://cloud.medroad.cn/
Abbreviations
- CI
- Confidence interval
- CNMTCM-CACMS
- China National Medical Team of Traditional Chinese Medicine of China Academy of Chinese Medical Sciences
- CONSORT
- Consolidated Standards of Reporting Trials
- COVID-19
- Coronavirus Disease 2019
- CT
- Computed tomography
- ECMO
- Extracorporeal membrane oxygenation
- FAS
- Full Analysis Set
- GCP
- Good Clinical Practice
- IQR
- Interquartile range
- NHC-NATCM-China guidelines
- National clinical practice guideline for COVID-19 in China” developed by the National Health Commission and the National Administration of TCM of the People’s Republic of China
- PPS
- Per-protocol Set
- RT-PCR
- Reverse-transcription polymerase chain reaction
- SCIO-China
- State Council Information Office of the People’s Republic of China
- TCM
- Traditional Chinese medicine
- WHO
- World Health Organization
